BrightGene Bio-Medical Technology Co.

Overview

• HeadquartersSuzhou, People's Republic of China¹
• Websitewww.bright-gene.com

See how the biggest companies compare on our leaderboards

Timeline

1. 2001Founded Founded¹

Calendar

Drug trials and FDA: coming up

1. Nov 14, 2026Phase 3 trial readout expected Phase 3 trial of Drug: 5 mg BGM0504 Administered SC and Drug: : 10 mg BGM0504 Administered SC in Type 2 Diabetes Mellitus (T2DM): primary completion expected Nov 14, 2026 (ClinicalTrials.gov NCT06716203).²
2. Nov 14, 2026Phase 3 trial readout expected Phase 3 trial of Drug: 5 mg BGM0504 Administered SC, Drug:10 mg BGM0504 Administered SC and others in Type 2 Diabetes Mellitus (T2DM): primary completion expected Nov 14, 2026 (ClinicalTrials.gov NCT06716216).³
3. Feb 28, 2027Phase 2 trial readout expected Phase 2 trial of BGM0504 tablets in Overweight or Obese Participants Without Diabetes: primary completion expected Feb 28, 2027 (ClinicalTrials.gov NCT07658560).⁴
4. Apr 30, 2027Phase 3 trial readout expected Phase 3 trial of BGM0504 and Semaglutide in Type 2 Diabetes (T2DM): primary completion expected Apr 30, 2027 (ClinicalTrials.gov NCT07064486).⁵

Drug trials and FDA: recently

1. Jan 14, 2026Phase 2 trial completed Phase 2 trial of BGM0504 and Tirzepatide in Obesity: primary completion Jan 14, 2026, no results posted yet (ClinicalTrials.gov NCT06911203).⁶

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Links

• Websitewww.bright-gene.com¹
• WikidataQ135183208